Capitalization 79.47L 58.19L 49Cr P/E ratio 2022
-1.26x
P/E ratio 2023 -2.01x
Enterprise value 47.73L 34.95L 29Cr EV / Sales 2022
-
EV / Sales 2023 -
Free-Float
85.86%
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.86%
1 week+12.09%
Current month+9.73%
1 month+10.36%
3 months-54.64%
6 months-89.34%
Current year-92.63%
More quotes
1 week
5.15
Extreme 5.15
6.59
1 month
4.85
Extreme 4.85
6.59
Current year
4.85
Extreme 4.85
96.20
1 year
4.85
Extreme 4.85
130.00
3 years
4.85
Extreme 4.85
183.95
5 years
4.85
Extreme 4.85
981.50
10 years
4.85
Extreme 4.85
12 281.16
More quotes
Director TitleAgeSince
Chief Executive Officer 54 20/94/20
Director of Finance/CFO 48 01/18/01
Chief Tech/Sci/R&D Officer - -
Manager TitleAgeSince
Founder 47 20/94/20
Chief Executive Officer 54 20/94/20
Director/Board Member 54 01/21/01
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-0.86%+12.09%-94.51%-95.14%79.47L
+1.17%-3.23%+27.98%+154.05%12TCr
+0.45%-4.48%+20.22%+81.82%11TCr
-0.60%-3.27%+1.99%+86.56%3.15TCr
+0.44%+1.35%+11.20%-50.58%2.89TCr
-3.62%+1.27%+35.38%-35.60%2.58TCr
+10.00%-.--%-39.24%-65.73%2.21TCr
+0.09%-1.02%-34.41%-42.35%1.49TCr
+2.33%-3.23%+1,064.67%+290.56%1.41TCr
+2.01%-4.73%+123.99%+355.78%1.34TCr
Average +1.12%+1.83%+111.73%+67.94% 3.74TCr
Weighted average by Cap. +0.99%-1.17%+58.85%+90.25%
See all sector performances

Financials

2022 2023
Net sales - -
Net income -2.36Cr -1.73Cr -145.06Cr -1.79Cr -1.31Cr -110.01Cr
Net Debt -1.65Cr -1.21Cr -101.17Cr -31.74L -23.24L -20Cr
More financial data * Estimated data
Logo Quantum BioPharma Ltd.
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
Employees
17
More about the company
Date Price Change Volume
08/24/08 5.750 $ -0.86% 911
07/24/07 5.800 $ -6.60% 2,080
04/24/04 6.210 $ +17.39% 9,125
03/24/03 5.290 $ +2.72% 1,249
02/24/02 5.150 $ +0.39% 1,231

Delayed Quote Canadian Securities Exchange, October 08, 2024 at 07:31 pm IST

More quotes